Integration of polygenic and gut metagenomic risk prediction for common diseases

Publication: Nature aging

Yang Liu, Scott C. Ritchie, Shu Mei Teo, Matti O. Ruuskanen, Oleg Kambur, Qiyun Zhu, Jon Sanders, Yoshiki Vázquez-Baeza, Karin Verspoor, Pekka Jousilahti, Leo Lahti, Teemu Niiranen, Veikko Salomaa, Aki S. Havulinna, Rob Knight, Guillaume Méric & Michael Inouye

25 March 2024

Summary

Researchers have shown that risk scores based on our genes and gut bacteria can improve the prediction of diseases such as type 2 diabetes and prostate cancer over traditional risk factors alone.

View publication

Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study

Publication: Nature Communications

Genevieve I. Cezard, Rachel E. Denholm, Rochelle Knight, Yinghui Wei, Lucy Teece, Renin Toms, Harriet J. Forbes, Alex J. Walker, Louis Fisher, Jon Massey, Lisa E. M. Hopcroft, Elsie M. F. Horne, Kurt Taylor, Tom Palmer, Marwa Al Arab, Jose Ignacio Cuitun Coronado, Samantha H. Y. Ip, Simon Davy, Iain Dillingham, Sebastian Bacon, Amir Mehrkar, Caroline E. Morton, Felix Greaves, Catherine Hyams, George Davey Smith, John Macleod, Nishi Chaturvedi, Ben Goldacre, William N. Whiteley, Angela M. Wood, Jonathan A. C. Sterne & Venexia Walker On behalf of the Longitudinal Health and Wellbeing and Data and Connectivity UK COVID-19 National Core Studies, CONVALESCENCE study and the OpenSAFELY collaborative

11 March 2024

Summary

Researchers looked at cardiovascular diseases in different vaccination and variant eras using linked electronic health records for ~40% of the English population. They studied distinct groups: a ‘pre-vaccination’ cohort in the wild-type/Alpha variant eras and ‘vaccinated’ and ‘unvaccinated’ cohorts in the Delta variant era.

They showed that people with COVID-19 are more likely to develop cardiovascular diseases in the first 4 weeks after diagnosis compared to people without COVID-19. The effects can be long lasting. The excess risk of cardiovascular disease remains elevated up to 6 months after COVID-19 diagnosis but it reduces over time. People who had COVID-19 in the wild-type/Alpha variant eras (before vaccination became available to them) are at higher risk of cardiovascular events up to two years after COVID-19.

View publication

Mitochondrial DNA variants modulate N-formylmethionine, proteostasis and risk of late-onset human diseases

Publication: Nature Medicine

Na Cai, Aurora Gomez-Duran, Ekaterina Yonova-Doing, Kousik Kundu, Annette I. Burgess, Zoe J. Golder, Claudia Calabrese, Marc J. Bonder, Marta Camacho, Rachael A. Lawson, Lixin Li, Caroline H. Williams-Gray, Emanuele Di Angelantonio, David J. Roberts, Nick A. Watkins, Willem H. Ouwehand, Adam S. Butterworth, Isobel D. Stewart, Maik Pietzner, Nick J. Wareham, Claudia Langenberg, John Danesh, Klaudia Walter, Peter M.Rothwell, Joanna M. M. Howson, Oliver Stegle, Patrick F. Chinnery & Nicole Soranzo

23 August 2021


Summary

Researchers have identified associations between mtDNA variants and an amino acid, N-formylmethionine (fMet), and effects of fMet on the risk of developing a range of common, late-onset illnesses. Read the full story.

View publication

Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease

Publication: The Journal of the American Medical Association (JAMA)

Brian A. Ference, Deepak L. Bhatt, Alberico L. Catapano, Chris J. Packard, Ian Graham, Stephen Kaptoge, Thatcher B. Ference, Qi Guo, Ulrich Laufs, Christian T. Ruff, Arjen Cupido1, G. Kees Hovingh, John Danesh, Michael V. Holmes, George Davey Smith, Kausik K. Ray, Stephen J. Nicholls, Marc S. Sabatine

2 September 2019


Summary:

Most cardiovascular events can be prevented with sustained exposure to modestly lower combinations of lipoprotein cholesterol
(LDL-C) and lower systolic blood pressure (SBP), according to research led by Cambridge researchers who carried out Mendelian randomization analyses involving 438,952 participants. Read the full story here.

View publication

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

Publication: Science

Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, DerOhannessian S, Kontush A, Surendran P, Saleheen D, Trompet S, Jukema JW, De Craen A, Deloukas P, Sattar N, Ford I, Packard C, Majumder Aa, Alam DS, Di Angelantonio E, Abecasis G, Chowdhury R, Erdmann J, Nordestgaard BG, Nielsen SF, Tybjærg-Hansen A, Schmidt RF, Kuulasmaa K, Liu DJ, Perola M, Blankenberg S, Salomaa V, Männistö S, Amouyel P, Arveiler D, Ferrieres J, Müller-Nurasyid M, Ferrario M, Kee F, Willer CJ, Samani N, Schunkert H, Butterworth AS, Howson JM, Peloso GM, Stitziel NO, Danesh J, Kathiresan S, Rader DJ; CHD Exome+ Consortium; CARDIoGRAM Exome Consortium; Global Lipids Genetics Consortium.

11 March 2016

View publication

© Copyright - NIHR Cambridge Biomedical Research Centre 2025